NAUT News and Press, Nautilus Biotechnology Inc. From 08/30/22

SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanle...

Nautilus Biotechnology, Inc. (NAUT) Q2 2022 Earnings Conference Call August 02, 2022 08:30 AM ET Company Participants Sujal Patel - Founder and Chief Executive Officer Anna Mowry - Chief Financial Officer Parag Mallick - Founder and Chief Scientist Conferen...

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...

Nautilus Biotechnology press release ( NASDAQ: NAUT ): Q2 GAAP EPS of -$0.12 beats by $0.05 . For further details see: Nautilus Biotechnology GAAP EPS of -$0.12 beats by $0.05

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights ...

SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments ...

Nautilus Biotechnology ( NASDAQ: NAUT ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$0.17 (+10.5% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen ...

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 20...

The NASDAQ is finally in formal bear market territory, although, as high growth investors fully know, we have been in a brutal bear market since at least November of 2021. My aggressive growth portfolio has not been spared the extreme pain; however, I am confident in my positions once...

Nautilus Biotechnology, Inc. (NAUT) Q1 2022 Earnings Conference Call May 3, 2022 8:30 a.m. ET Company Participants Sujal Patel - Co-Founder & CEO Anna Mowry - CFO Parag Mallick - Co-Founder & Chief Scientific Officer Conference Call Participants Matt Kim - Jefferies Stephanie Yan - Co...